PT1442024E - Derivados aminobenzamida como inibidores da glicogénio sintase quinase 3$g(b) - Google Patents
Derivados aminobenzamida como inibidores da glicogénio sintase quinase 3$g(b) Download PDFInfo
- Publication number
- PT1442024E PT1442024E PT02802307T PT02802307T PT1442024E PT 1442024 E PT1442024 E PT 1442024E PT 02802307 T PT02802307 T PT 02802307T PT 02802307 T PT02802307 T PT 02802307T PT 1442024 E PT1442024 E PT 1442024E
- Authority
- PT
- Portugal
- Prior art keywords
- inhibitors
- glycogen synthase
- synthase kinase
- aminobenzamide derivatives
- aminobenzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01204192 | 2001-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1442024E true PT1442024E (pt) | 2008-06-12 |
Family
ID=8181175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02802307T PT1442024E (pt) | 2001-11-01 | 2002-10-29 | Derivados aminobenzamida como inibidores da glicogénio sintase quinase 3$g(b) |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20060063789A1 (pt) |
| EP (1) | EP1442024B1 (pt) |
| JP (1) | JP2005507420A (pt) |
| KR (1) | KR20040062557A (pt) |
| CN (1) | CN100436427C (pt) |
| AT (1) | ATE389638T1 (pt) |
| AU (1) | AU2002363177B2 (pt) |
| BR (1) | BR0213790A (pt) |
| CA (1) | CA2463823A1 (pt) |
| DE (1) | DE60225709T2 (pt) |
| DK (1) | DK1442024T3 (pt) |
| EA (1) | EA007063B1 (pt) |
| ES (1) | ES2303565T3 (pt) |
| HU (1) | HUP0402245A3 (pt) |
| IL (1) | IL161663A0 (pt) |
| MX (1) | MXPA04004176A (pt) |
| NO (1) | NO326889B1 (pt) |
| NZ (1) | NZ531854A (pt) |
| PL (1) | PL368920A1 (pt) |
| PT (1) | PT1442024E (pt) |
| WO (1) | WO2003037877A1 (pt) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2477604A1 (en) | 2002-03-13 | 2003-09-25 | Signum Biosciences, Inc. | Modulation of protein methylation and phosphoprotein phosphate |
| CA2502970A1 (en) * | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| DE10322911A1 (de) * | 2003-05-21 | 2004-12-16 | Bayer Materialscience Ag | Verfestigungsstabile blockierte Polyisocyanate |
| DK1660458T3 (da) * | 2003-08-15 | 2012-05-07 | Irm Llc | 2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet. |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7923041B2 (en) | 2005-02-03 | 2011-04-12 | Signum Biosciences, Inc. | Compositions and methods for enhancing cognitive function |
| EP1843734A4 (en) * | 2005-02-03 | 2008-09-10 | Signum Biosciences Inc | COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS |
| EP1885454A2 (en) | 2005-05-04 | 2008-02-13 | DeveloGen Aktiengesellschaft | Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders |
| EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| ES2633318T3 (es) | 2006-10-23 | 2017-09-20 | Cephalon, Inc. | Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met |
| TW200902010A (en) | 2007-01-26 | 2009-01-16 | Smithkline Beecham Corp | Anthranilamide inhibitors of aurora kinase |
| US8242271B2 (en) | 2007-06-04 | 2012-08-14 | Avila Therapeutics, Inc. | Heterocyclic compounds and uses thereof |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| CA2702674C (en) | 2007-10-19 | 2016-05-03 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| WO2009071535A1 (en) * | 2007-12-03 | 2009-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| CN102014897B (zh) | 2008-04-21 | 2015-08-05 | 西格纳姆生物科学公司 | 化合物、组合物和其制备方法 |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2011103196A1 (en) * | 2010-02-17 | 2011-08-25 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| AU2011254550B2 (en) | 2010-05-21 | 2013-11-07 | Noviga Research Ab | Novel pyrimidine derivatives |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| EP3363437B8 (en) | 2011-02-18 | 2021-11-03 | Endo Pharmaceuticals Inc. | Aminoindane compounds and use thereof in treating pain |
| EP2688883B1 (en) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Pyrimidine derivatives |
| WO2014028675A1 (en) | 2012-08-15 | 2014-02-20 | Endo Pharmaceuticals Inc. | Use of aminoindane compounds in treating overactive bladder and interstitial cystitis |
| KR20150046259A (ko) | 2012-08-23 | 2015-04-29 | 앨리오스 바이오파마 인크. | 파라믹소바이러스 바이러스성 감염의 치료용 화합물 |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| TW201620887A (zh) | 2014-01-10 | 2016-06-16 | 葛蘭素史克智慧財產（第二）有限公司 | 化合物及方法 |
| WO2017156527A1 (en) * | 2016-03-11 | 2017-09-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease |
| CN106632021A (zh) * | 2016-09-27 | 2017-05-10 | 中国药科大学 | 2‑取代异烟酸类化合物、其制备方法及其用途 |
| US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| CN112876420B (zh) * | 2019-11-29 | 2023-01-24 | 沈阳化工研究院有限公司 | 一种硫代苯甲酰衍生物及其应用 |
| WO2021155185A1 (en) * | 2020-01-30 | 2021-08-05 | Sumitomo Dainippon Pharma Oncology, Inc. | Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors |
| CN114105887B (zh) * | 2021-09-16 | 2023-12-01 | 沈阳药科大学 | 一种氨基嘧啶衍生物及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0164204A1 (en) * | 1984-05-12 | 1985-12-11 | FISONS plc | Novel pharmaceutically useful pyrimidines |
| EP0162204A3 (de) * | 1984-05-22 | 1988-07-06 | Franz Grimme Landmaschinenfabrik GmbH & Co. KG. | Riemenschloss für Riemen von Siebkettenförderbändern |
| SG47583A1 (en) * | 1986-01-13 | 1998-04-17 | American Cyanamid Co | 4,5,6-Substituted-n- (substituted-phenyl) -2- pyrimidinamines |
| US4966622A (en) * | 1988-04-12 | 1990-10-30 | Ciba-Geigy Corporation | N-phenyl-N-pyrimidin-2-ylureas |
| GB9012592D0 (en) * | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
| US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| AU751573C (en) * | 1998-03-27 | 2003-10-09 | Janssen Pharmaceutica N.V. | HIV inhibiting pyrimidine derivatives |
| WO1999065897A1 (en) * | 1998-06-19 | 1999-12-23 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| NZ526542A (en) * | 2000-12-21 | 2005-01-28 | Glaxo Group Ltd | Pyrimidineamines as angiogenesis modulators |
| US20030139435A1 (en) * | 2001-06-26 | 2003-07-24 | Gulzar Ahmed | N-heterocyclic inhibitors of TNF-alpha expression |
| US6939874B2 (en) * | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
| JP4460292B2 (ja) * | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
-
2002
- 2002-10-29 EA EA200400616A patent/EA007063B1/ru not_active IP Right Cessation
- 2002-10-29 KR KR10-2004-7004829A patent/KR20040062557A/ko active IP Right Grant
- 2002-10-29 HU HU0402245A patent/HUP0402245A3/hu unknown
- 2002-10-29 DK DK02802307T patent/DK1442024T3/da active
- 2002-10-29 CN CNB028219163A patent/CN100436427C/zh not_active Expired - Fee Related
- 2002-10-29 JP JP2003540159A patent/JP2005507420A/ja active Pending
- 2002-10-29 NZ NZ531854A patent/NZ531854A/xx not_active IP Right Cessation
- 2002-10-29 MX MXPA04004176A patent/MXPA04004176A/es active IP Right Grant
- 2002-10-29 ES ES02802307T patent/ES2303565T3/es not_active Expired - Lifetime
- 2002-10-29 EP EP02802307A patent/EP1442024B1/en not_active Expired - Lifetime
- 2002-10-29 PT PT02802307T patent/PT1442024E/pt unknown
- 2002-10-29 IL IL16166302A patent/IL161663A0/xx unknown
- 2002-10-29 WO PCT/EP2002/012079 patent/WO2003037877A1/en active IP Right Grant
- 2002-10-29 PL PL02368920A patent/PL368920A1/xx not_active Application Discontinuation
- 2002-10-29 DE DE60225709T patent/DE60225709T2/de not_active Expired - Lifetime
- 2002-10-29 AU AU2002363177A patent/AU2002363177B2/en not_active Ceased
- 2002-10-29 CA CA002463823A patent/CA2463823A1/en not_active Abandoned
- 2002-10-29 US US10/493,446 patent/US20060063789A1/en not_active Abandoned
- 2002-10-29 AT AT02802307T patent/ATE389638T1/de active
- 2002-10-29 BR BR0213790-9A patent/BR0213790A/pt not_active IP Right Cessation
-
2004
- 2004-06-01 NO NO20042253A patent/NO326889B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003037877A1 (en) | 2003-05-08 |
| JP2005507420A (ja) | 2005-03-17 |
| AU2002363177B2 (en) | 2008-09-18 |
| EP1442024A1 (en) | 2004-08-04 |
| KR20040062557A (ko) | 2004-07-07 |
| CN100436427C (zh) | 2008-11-26 |
| EP1442024B1 (en) | 2008-03-19 |
| DE60225709T2 (de) | 2009-05-07 |
| PL368920A1 (en) | 2005-04-04 |
| ES2303565T3 (es) | 2008-08-16 |
| NO20042253L (no) | 2004-06-01 |
| DK1442024T3 (da) | 2008-06-30 |
| CA2463823A1 (en) | 2003-05-08 |
| IL161663A0 (en) | 2004-09-27 |
| EA007063B1 (ru) | 2006-06-30 |
| NO326889B1 (no) | 2009-03-16 |
| US20060063789A1 (en) | 2006-03-23 |
| DE60225709D1 (de) | 2008-04-30 |
| HUP0402245A2 (hu) | 2005-02-28 |
| MXPA04004176A (es) | 2004-09-06 |
| CN1703405A (zh) | 2005-11-30 |
| ATE389638T1 (de) | 2008-04-15 |
| EA200400616A1 (ru) | 2004-08-26 |
| BR0213790A (pt) | 2004-12-07 |
| NZ531854A (en) | 2006-03-31 |
| HUP0402245A3 (en) | 2010-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1442024E (pt) | Derivados aminobenzamida como inibidores da glicogénio sintase quinase 3$g(b) | |
| IL163777A0 (en) | Kinase inhibitors | |
| IL163781A0 (en) | Purine derivatives as kinase inhibitors | |
| MXPA03010207A (es) | Nuevas 4-anilinoquinolin-3-carboxamidas. | |
| IL160915A0 (en) | Indolizines inhibiting kinase proteins | |
| MY141255A (en) | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs | |
| WO2001019828A3 (en) | Kinase inhibitors as therapeutic agents | |
| YU57603A (sh) | Inhibitori fosfodiesteraze 4 | |
| GB0100889D0 (en) | Compounds | |
| GB0124627D0 (en) | Novel compounds | |
| ATE409189T1 (de) | Farnesyl transferase-hemmende 6- heterocyclylmethyl-chinolin und chinazol-derivate | |
| TNSN04141A1 (en) | NEW COMPOUNDS - DDP - IV difluor | |
| MXPA05011296A (es) | Conjugados de fosfonato inhibidores de la cinasa. | |
| AP1699A (en) | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
| MY143516A (en) | Kinase inhibitors | |
| PL361404A1 (en) | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases | |
| MXPA04003886A (es) | Tiofen- y tiazolsulfonamidas como agentes antineoplasticos. | |
| MY140572A (en) | Quinazolinone derivatives as parp inhibitors | |
| WO2002020489A3 (en) | QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE | |
| GB0127903D0 (en) | Improvements relating to organic compounds | |
| ZA200404752B (en) | 6-aminomorphinane derivatives method for the production and use thereof | |
| DE60229420D1 (de) | Neue metallproteinaseinhibitoren | |
| IL157216A0 (en) | Crystalline forms of pyrimidine nucleoside derivatives and pharmaceutical compositions containing the same | |
| GB0215392D0 (en) | Chemical compounds | |
| LT2003075A (en) | Inhibitor of monoamine uptake |